New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
08:33 EDTCBMGCellular Biomedicine completes enrollment in ReJoin Phase IIb clinical trial
Cellular Biomedicine has completed the patient enrollment required for its Phase IIb trial to further evaluate the safety and efficacy of their proprietary adipose-derived mesenchymal precursor cell-based therapy ReJoin for Knee Osteoarthritis. The Phase I/IIa clinical trial for this therapy was completed in 4Q13. The primary endpoints for this trial are knee-related pain, stiffness and function.
News For CBMG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 16, 2014
08:35 EDTCBMGCellular Biomedicine launches pre-clinical research study for COPD
Cellular Biomedicine announced the launch of a pre-clinical study of human adipose-derived mesenchymal progenitor cell, or haMPC, therapy for Chronic Obstructive Pulmonary Disease, or COPD. The study will evaluate the safety and efficacy of haMPCs to treat COPD. The pre-clinical study will be conducted by Shanghai First People's Hospital, a leading teaching hospital affiliated with Shanghai Jiaotong University. Professor Zhou Xin, director of the hospital's respiratory department and chairperson of Respiratory Diseases Division of Shanghai Medical Association, will lead the study as Principal Investigator. Prof. Zhou is also currently leading the Company's pre-clinical study on adipose derived mesenchymal progenitor cell therapy for asthma.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use